Candel Therapeutics
OverviewSuggest Edit
Candel Therapeutics is a biotechnology company developing the Gene Mediated Cytotoxic Immunotherapy (GMCI™) and the oncolytic rQNestin34.5 platforms for the treatment of solid tumors. The Company's lead programs include two randomized studies in prostate cancer, including a Phase 3 under an FDA approved special protocol assessment, as well as ongoing clinical programs in glioma, lung and pancreatic cancer.
| Type | Private | |
| HQ | Arlington, US | Map |
| Website | candeltx.com |
Locations
Candel Therapeutics Office Locations
Candel Therapeutics Financials and Metrics
Summary Metrics
Candel Therapeutics total Funding | $51.2 m |
Candel Therapeutics latest funding size | $22.50 m |
Time since last funding | a year ago |
Candel Therapeutics investors | Sands Capital Ventures, PBM Capital Group, Northpond Ventures, H7 Holdings, Level One Partners |
Candel Therapeutics Online and Social Media Presence
Candel Therapeutics's Trends
Candel Therapeutics Frequently Asked Questions
Who are Candel Therapeutics competitors?
Competitors of Candel Therapeutics include Mendel.ai, Lipella Pharmaceuticals and Immundnz.
Where is Candel Therapeutics headquarters?
Candel Therapeutics headquarters is located at Rosslyn, Arlington.
Where are Candel Therapeutics offices?
Candel Therapeutics has offices in Arlington and Needham.
How many offices does Candel Therapeutics have?
Candel Therapeutics has 2 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies